Press Release Archives | Page 7 of 23

Oncotarget News

Oncotarget Sponsors 19th International p53 Workshop in Italy

April 29, 2024

Oncotarget is a contributing sponsor at the 19th International p53 Workshop in Trieste, Italy, on May 13–16, 2024.BUFFALO, NY- April 29, 2024 – Oncotarget is a contributing sponsor at... read more

Figure 7: B-cell depletion of BTA106 in cynomolgus monkeys.

Oncotarget

Novel Therapeutic Bispecific Antibodies for B-cell Lymphoma

April 16, 2024

Our results indicate that IgM-dependent bispecific antibodies are potent therapeutic agents for B-cell malignancies.”BUFFALO, NY- April 16, 2024 – A new research paper was published in Oncotarget's Volume 15 on... read more

Figure 2: Effect of treatment with MIA-602 on the growth of Doxorubicin-resistant K-562 tumors xenographed into nude mice.

Oncotarget

Exploring the Role of MIA-602 in Overcoming Doxorubicin-resistance in Acute Myeloid Leukemia

April 10, 2024

Our results reveal that MIA-602 may be a useful treatment for Doxorubicin-resistant AML [...]”BUFFALO, NY- April 10, 2024 – A new research paper was published in Oncotarget's Volume 15 on April... read more

Figure 2: Analysis of immune cell subsets during neoadjuvant therapy.

Oncotarget

Durvalumab and Tremelimumab Before Surgery in Patients With HR+/HER2-negative Breast Cancer

March 27, 2024

this trial was stopped early after 3 of the first 8 enrolled patients experienced immunotherapy-related toxicity or suspected disease progression [...]”BUFFALO, NY- March 27, 2024 – A new research paper was... read more

Figure 6: Effects of various drug combinations on molecular markers of apoptosis in patient-derived cell samples.

Oncotarget

ABT199/Venetoclax Synergism With Thiotepa in Acute Myeloid Leukemia (AML) Cells

March 25, 2024

the combination of ABT199/venetoclax and Thio enhances the cytotoxicity of (Flu+Clad+Bu) in AML cell lines and leukemia patient-derived cell samples.”BUFFALO, NY- March 25, 2024 – A new... read more

Figure 8: Major analytical performance measurements of the NeXT Personal® assay.

Oncotarget

Analytical Validation of an Ultra-sensitive Personalized Circulating Tumor DNA Assay: NeXT Personal®

March 20, 2024

These results suggest strong potential for clinical use of the assay in ctDNA monitoring of solid tumor cancers.”BUFFALO, NY- March 20, 2024 – A new research paper was published in... read more

Figure 2: Preemptive combinations. (A) EGFR-Mutant-Driven NSCLC. See text. (B) METex14-Driven NSCLC. See text.

Oncotarget

“From Osimertinib to Preemptive Combinations” by Dr. Blagosklonny

March 19, 2024

Here I will re-introduce the notion of preemptive combinations (PC) of targeted drugs.”BUFFALO, NY- March 19, 2024 – A new research perspective was published by Mikhail V. Blagosklonny M.D.,... read more

Figure 2: A comparative analysis of G4 landscape in cultured cells using AbC G4-ChIP. antibody

Oncotarget

A New Antibody Capture Method Reveals G-quadruplex Landscape and its Regulation

March 18, 2024

we present an improved method for G4 landscape determination and by applying it we show that sequence property-specific constraints of the nuclear environment mitigate G4 formation.”BUFFALO, NY- March 18,... read more

Oncotarget

Oncotarget at AACR Annual Meeting 2024

March 11, 2024

BUFFALO, NY- March 11, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences with a focus on all areas of cancer and aging research. Oncotarget is one of the... read more

Figure 7: ER stress signaling plays an important role in mediating GZ17-6.02/bortezomib lethality

Oncotarget

GZ17-6.02 With Proteasome Inhibitors Kills Multiple Myeloma Cells

March 6, 2024

We believe that developing GZ17-6.02 as a novel multiple myeloma agent potentially opens up a multitude of novel opportunities to develop therapeutic approaches which will prolong patient survival.”BUFFALO,... read more